Amphastar Pharmaceuticals, Inc.
AMPHNASDAQHealthcare● Active
$19.39
$-0.35(-1.77%)
Market Cap$854961699
P/E Ratio—
52W High$31.26
52W Low$16.65
Amphastar Pharmaceuticals, Inc. (AMPH) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMPH · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.10B | $0.16B | $0.14B | $0.09B | $0.06B |
| Depreciation & Amort. | $0.06B | $0.06B | $0.04B | $0.03B | $0.03B |
| Stock-Based Comp. | $0.03B | $0.02B | $0.02B | $0.02B | $0.02B |
| Change in Working Capital | ($0.07B) | ($0.01B) | ($0.02B) | ($0.03B) | ($0.00B) |
| Net Cash from Operations | $0.16B | $0.21B | $0.18B | $0.09B | $0.10B |
| Investing Activities | |||||
| Capital Expenditure | ($0.03B) | ($0.04B) | ($0.04B) | ($0.02B) | ($0.03B) |
| Purchases of Investments | ($0.12B) | ($0.08B) | ($0.14B) | ($0.04B) | ($0.02B) |
| Sales of Investments | $0.09B | $0.13B | $0.04B | $0.03B | $0.02B |
| Net Cash from Investing | ($0.07B) | ($0.12B) | ($0.65B) | ($0.03B) | ($0.03B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.08B) | ($0.09B) | ($0.06B) | ($0.04B) | ($0.03B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.01B | $0.01B | $0.53B | ($0.00B) | $0.03B |
| Net Cash from Financing | ($0.07B) | ($0.08B) | $0.45B | ($0.03B) | ($0.04B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.12B | $0.17B | $0.15B | $0.07B | $0.07B |
| FCF Margin %(computed) | 16.84% | 23.55% | 22.55% | 13.06% | 16.11% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Amphastar Pharmaceuticals, Inc. data
About Amphastar Pharmaceuticals, Inc. (AMPH) Cash Flow Statement
Amphastar Pharmaceuticals, Inc. generated operating cash flow of $0.16B and free cash flow of $0.12B for 2025 — a FCF margin of 16.84%. Capital expenditure was ($0.03B).
Frequently asked questions
AMPH · 4 questionsAmphastar Pharmaceuticals, Inc. generated free cash flow of $0.12B for 2025, down 29.7% year-over-year.
AMPH free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10